A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA

Trial Profile

A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SOCRATES
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Jul 2017 Results of post hoc-exploratory analysis assessing efficacy of ticagrelor versus aspirin among patients with embolic stroke of unknown source, published in the Stroke Journal.
    • 24 Feb 2017 Results of pre-specified exploratory analysis (n=3081) presented at the 42nd International Stroke Conference
    • 29 Nov 2016 Results of subgroup analysis (Asian patients, n=3858) of SOCRATES Trial published in the Stroke.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top